CLINICAL STUDIES OF L-105 ON RESPIRATORY TRACT INFECTION

Clinical studies of L-105, a new cephalosporin were carried out in the field of respiratory tract infection and the following results were obtained. I. L-105 was administered to 8 cases with bacterial pneumonia, one case with lung abscess and one case with chronic bronchitis at a dosage of 2-4 g/day...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 34; no. Supplement3; pp. 161 - 164
Main Authors AKAISHI, TADAYUKI, ISHIDA, SAKAE, FUJIKANE, TOSHIAKI, MINAMI, HIROAKI, ONODERA, SOKICHI, NAKANO, HITOSHI, TAKASHIO, TETSUYA, SASAKI, NOBUHIRO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1986
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.34.Supplement3_161

Cover

More Information
Summary:Clinical studies of L-105, a new cephalosporin were carried out in the field of respiratory tract infection and the following results were obtained. I. L-105 was administered to 8 cases with bacterial pneumonia, one case with lung abscess and one case with chronic bronchitis at a dosage of 2-4 g/day by intravenous drip infusion for 8-14 days. 2. Clinical response of L-105 was excellent in 3 cases, good in 3 cases, fair in 2 cases, poor in one case and undetermined in one case. The efficacy rate was 67%. 3. Skin eruption was observed in one case with autosensitization dermatitis, and slight elevation of GOT, GPT, BUN and eosinophil were observed in two, one and two cases, respectively.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.34.Supplement3_161